CoChat

BRCA1/BRCA2 Germline Mutations in Locally Recurrent Breast Cancer Patients After Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients With BRCA1/BRCA2 Mutations

Turner, Bruce C., Harrold, Elizabeth, Matloff, Ellen, Smith, Tanya, Gumbs, Andrew A., Beinfield, Malcom, Ward, Brian, Skolnick, Mark, Glazer, Peter M., Thomas, Alun, Haffty, Bruce G. · 1999 · Journal of Clinical Oncology
Cited by 109

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

PURPOSE: Breast cancer patients treated conservatively with lumpectomy and radiation therapy (LRT) have an estimated lifetime risk of local relapse (ipsilateral breast tumor recurrence [IBTR]) of 10% to 15%. For breast cancer patients carrying BRCA1 or BRCA2 (BRCA1/2) mutations, the outcome of treatment with LRT with respect to IBTR has not been determined. In this study, we estimate the frequency of BRCA1/2 mutations in a study of breast cancer patients with IBTR treated with LRT. PATIENTS AND METHODS: Between 1973 and 1994, there were 52 breast cancer patients treated with LRT who developed an IBTR within the prior irradiated breast and who were willing to participate in the current study. From our database, we also identified 52 control breast cancer patients treated with LRT without IBTR. The control patients were individually matched to the index cases with respect to multiple clinical and pathologic parameters. Lymphocyte DNA specimens from all 52 locally recurrent patients and 15 of the matched control patients under age 40 were used as templates for polymerase chain reaction amplification and dye-primer sequencing of exons 2 to 24 of BRCA1, exons 2 to 27 of BRCA2, and flanking intron sequences. RESULTS: After LRT, eight (15%) of 52 breast cancer patients had IBTR with deleterious BRCA1/2 mutations. By age, there were six (40%) of 15 patients with IBTR under age 40 with BRCA1/2 mutations, one (9.0%) of 11 between ages 40 and 49, and one (3.8%) of 26 older than age 49. In comparison to the six (40%) of 15 of patients under age 40 with IBTR found to have BRCA1/2 mutations, only one (6.6%) of 15 matched control patients without IBTR and had a BRCA1/2 mutation (P = .03). The median time to IBTR for patients with BRCA1/2 mutations was 7.8 years compared with 4.7 years for patients without BRCA1/2 mutations (P = .03). By clinical and histologic criteria, these relapses represented second primary tumors developing in the conservatively treated breast. All patients with BRCA1/2 mutations and IBTR underwent successful surgical salvage mastectomy at the time of IBTR and remain alive without evidence of local or systemic progression of disease. CONCLUSION: In this study, we found an elevated frequency of deleterious BRCA1/2 mutations in breast cancer patients treated with LRT who developed late IBTR. The relatively long time to IBTR, as well as the histologic and clinical criteria, suggests that these recurrent cancers actually represent new primary breast cancers. Early onset breast cancer patients experiencing IBTR have a disproportionately high frequency of deleterious BRCA1/2 mutations. This information may be helpful in guiding management in BRCA1 or BRCA2 patients considering breast-conserving therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1999.17.10.3017

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 33

  1. 10.1056/NEJM198107023050102 · DOI · Paper page
  2. Fischer B, Redmond C, Poisson R, et al: Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 820:822,1989-828, · DOI · Paper page
  3. 10.1002/1097-0142(19891201)64:11<2217::AID-CNCR2820641106>3.0.CO;2-2 · doi:10.1002/1097-0142(19891201)64:11<2217::aid-cncr2820641106>3.0.co;2-2
  4. 10.1016/0140-6736(91)90475-5 · DOI · Paper page
  5. 10.1016/0360-3016(91)90774-X · doi:10.1016/0360-3016(91)90774-x
  6. 10.1200/JCO.1996.14.1.52 · doi:10.1200/jco.1996.14.1.52
  7. 10.1016/0360-3016(93)90382-6 · doi:10.1016/0360-3016(93)90382-6
  8. 10.1016/0360-3016(96)00150-2 · doi:10.1016/0360-3016(96)00150-2
  9. 10.1002/1097-0142(19840301)53:5<1049::AID-CNCR2820530506>3.0.CO;2-O · DOI · Paper page
  10. 10.1016/0360-3016(91)90772-V · doi:10.1016/0360-3016(91)90772-v
  11. Kurtz JM, Spitalier JM, Amalric R, et al: Mammary recurrences in women younger than forty. Int J Radiat Oncol Biol Phys 15:271,1998-276, · doi:10.1016/s0360-3016(98)90004-9
  12. 10.1016/0360-3016(94)90515-0 · DOI · Paper page
  13. 10.1111/j.1524-4741.1995.tb00241.x · doi:10.1111/j.1524-4741.1995.tb00241.x
  14. 10.1200/JCO.1998.16.6.2045 · DOI
  15. 10.1111/j.1524-4741.1996.tb00104.x · DOI
  16. 10.1016/0360-3016(91)90773-W · doi:10.1016/0360-3016(91)90773-w
  17. 10.1126/science.2270482 · DOI · Paper page
  18. 10.1126/science.7545954 · DOI · Paper page
  19. 10.1038/378789a0 · DOI · Paper page
  20. 10.1038/ng0396-333 · DOI · Paper page
  21. 10.1056/NEJM199601183340302 · DOI · Paper page
  22. Tonin P, Weber B, Offit K, et al: Frequency of recurrent and mutations in Ashkenazi Jewish breast cancer families. Nat Med 11:1179,1996-1183, BRCA1 BRCA2 · DOI · Paper page
  23. 10.1016/S0140-6736(96)91484-1 · DOI
  24. 10.1056/NEJM199705153362002 · DOI · Paper page
  25. 10.1002/bjs.1800811038 · DOI · Paper page
  26. 10.1001/jama.1995.03520310033026 · DOI · Paper page
  27. 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W · DOI · Paper page
  28. 10.1056/NEJM199705153362022 · DOI · Paper page
  29. 10.1200/JCO.1998.16.3.979 · doi:10.1200/jco.1998.16.3.979
  30. 10.1200/JCO.1998.16.1.115 · DOI
  31. 10.1007/BF01810778 · DOI
  32. 10.1016/S0167-8140(98)00023-1 · DOI
  33. 10.1001/jama.1997.03550150046034 · DOI · Paper page

Cited by

See all 109

Metadata

Authors
Turner, B. C., Harrold, E., Matloff, E., Smith, T., Gumbs, A. A., Beinfield, M., Ward, B., Skolnick, M., Glazer, P. M., Thomas, A., & Haffty, B. G.
Venue
Journal of Clinical Oncology
Published
1999-10
Volume
17
Issue
10
Pages
3017-3024
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1919554514
Cited by
109
References
2
FWCI
5.74
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRCA1/BRCA2 Germline Mutations in Locally Recurrent Breast Cancer Patients After Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients With BRCA1/BRCA2 Mutations. https://app.cochat.ai/papers/10.1200/jco.1999.17.10.3017
The paper
Turner, B. C., Harrold, E., Matloff, E., Smith, T., Gumbs, A. A., Beinfield, M., Ward, B., Skolnick, M., Glazer, P. M., Thomas, A., & Haffty, B. G. (1999). BRCA1/BRCA2 Germline Mutations in Locally Recurrent Breast Cancer Patients After Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients With BRCA1/BRCA2 Mutations. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1999.17.10.3017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.